Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 14th Preview)
-
Regulatory actions in neuro/rare disease
FDA has granted approval to Scholar Rock’s Isembyld (apitegromab), marking the first muscle-targeted treatment for spinal muscular atrophy and arriving after prior manufacturing setbacks. The drug is designed to improve motor function in people with SMA who are already on standard therapies. In parallel, Novartis delivered an update on del-desiran in the Phase III HARBOR trial for myotonic dystrophy type 1 (DM1). The study missed its primary endpoint on video hand opening time (vHOT), though the company reported evidence of clinical activity in secondary endpoints as it evaluates the full dataset with health authorities.
-
Oncology trial signals: wins, misses, and pipeline readouts
Oncologists saw a mixed bag of late-breaking data as companies reported both setbacks and trial progress across solid tumors and targeted approaches. AstraZeneca also posted disappointing late-stage results for Etcamah (an estrogen/progesterone receptor pathway SERD, per the report), with the company saying the drug failed a Phase III study intended to support a label expansion earlier in the treatment setting. Elsewhere, MediLink reported a Phase III win in small-cell lung cancer with a Roche-partnered B7-H3-directed antibody-drug conjugate, though cross-trial survival comparisons trailed GSK’s rival asset. Separately, Triana Biomedicines disclosed preclinical results positioning its brain-penetrant ALK fusion protein degrader TRI-611 as an alternative to ALK TKIs, using a molecular glue mechanism that draws ALK to cereblon for degradation.
-
FDA study clearance and IND moves in gene/cell therapy
New FDA clearance actions pushed several platform and investigational programs closer to human testing. The FDA cleared the University of Colorado Anschutz to run a CAR T-cell study in adults with advanced colorectal cancer and pediatric patients with solid cancers who have exhausted standard options. The move adds another academic CAR-T route into harder-to-treat solid tumor settings. Prelude Therapeutics also announced IND clearance for PRT-13722, an oral KAT6A selective degrader for HR+/HER2− breast cancer, extending the growing wave of targeted degraders into earlier clinical stages. Together, the updates highlight continued regulatory momentum for both cell therapies and protein-degradation approaches.
-
Biotech pivot and strategic transformation
Cellectis announced a strategic transformation that affects its entire development posture, shifting away from allogeneic CAR-T into in vivo gene editing. The company cited the momentum of its preclinical proof of concept for its severe dyslipidemia programs (including .HEAL-101 and .HEAL-201) to support the new in vivo focus. In a separate re-positioning within the cell-therapy landscape, Cellectis also moved to “offload” lead CAR-T work and emphasize in vivo approaches—reinforcing that competitive dynamics and technical timelines are driving platform-level reallocation across the donor-derived cell therapy space.
-
Clinical neuroscience and gene/epigenome editing collaborations
Modalis and Exegenesis Bio expanded their collaboration to push MDL-201 toward the clinic for Duchenne muscular dystrophy. The program uses Modalis’ epigenome editing technology to sustainably and selectively activate utrophin in muscle tissue—an approach aimed at improving dystrophic outcomes beyond direct exon-skipping. Funding also moved in Fragile X syndrome as Connecta Therapeutics secured $3.5 million to accelerate clinical development of CTH120 for adult males with Fragile X. The financing is positioned to complete a Phase IIa trial and support next-stage work tied to the FRAXCURE project funded by the EIC Accelerator program.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.